Should You Buy Regeneron Pharmaceuticals Stock Before Oct. 30?
The healthcare company will release its third-quarter results next month.
Overview
Regeneron Pharmaceuticals' (NASDAQ:REGN) stock is having an underwhelming year, down around 1% thus far. It's been a quality growth stock to own for the long haul, and with some terrific assets in its portfolio, it has the potential to perform much better in the long run.
Next month, on Oct. 30, it will release its third-quarter earnings results. A solid round of results could be just what's needed for the healthcare stock to rally. Is it a good buy before then?
Image source: Getty Images.
Details
Source
Originally published at www.fool.com.
Related Articles
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.